AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01290939 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Study NCT01290939 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
Study NCT05832905 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mobile and Wearable-assisted Case Management
Description: The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group
Study NCT04310605 — intervention group
Intervention type: BEHAVIORAL
Intervention: CBT 1
Description: CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Administered subcutaneously in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Administered orally in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered orally in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered intravenously or orally in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Administered orally in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
Study NCT01290939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT04310605 — intervention group
Intervention type: BEHAVIORAL
Intervention: CBT 2
Description: Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
Study NCT01629290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Pro
Description: Varnish treatment containing 5% NaF
Study NCT01629290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: Varnish treatment containing 5% NaF
Study NCT01290939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT01290939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Study NCT01290939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive assessment
Study NCT01290939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01290939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT01150448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate Treatment A
Description: All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
Study NCT01150448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate Treatment B
Description: Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
Study NCT02661126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
Study NCT01629290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanish
Description: Varnish treatment containing 5% NaF
Study NCT01629290 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bland varnish containing no NaF
Study NCT01273623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: to perform atherectomy on calcified lesions
Study NCT05660005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Stretching
Description: Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
Study NCT05660005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Myofascial Release
Description: The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
Study NCT05660005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercises
Description: The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
Study NCT01649141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
Study NCT03270176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
Study NCT03270176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenous infusion every 2 weeks.
Study NCT02271555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthetic induction will be achieved via 8% sevoflurane
Study NCT02271555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Anesthetic induction will be achieved via 8% sevoflurane
Study NCT02271555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
Study NCT02271555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
Study NCT00991198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical oxygen
Description: 0.5% concentration of Topical oxygen
Study NCT00991198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical oxygen
Description: 0.25% concentration topical oxygen
Study NCT00991198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no O2
Study NCT01901055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
Study NCT01901055 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Description: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
Study NCT01901055 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-CPAP
Description: Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
Study NCT01901055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
Study NCT01901055 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes Education
Description: Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
Study NCT01448135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VITAL AF
Description: Semi-elemental, high protein, and high omega-3 fish oil enteral formula
Study NCT03152838 — intervention group
Intervention type: GENETIC
Intervention: DNA methylation and Real-time Polymerase Chain Reaction Analysis
Description: Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes.
Study NCT01448135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osmolite 1.2
Description: High protein enteral formula
Study NCT00841256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen allergens in a water/glycerol solution
Description: In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
Study NCT03152838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gilliam Autism Rating Scale Arabic version
Description: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.~The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt.
Study NCT00235014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trandolapril/verapamil
Description: 180/2 mg QD
Study NCT00235014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet QD
Study NCT00235014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verapamil
Description: SR 240 mg QD
Study NCT05264064 — intervention group
Intervention type: OTHER
Intervention: The motor assessment to establish validation of the Polish version of the AIMS
Description: The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
Study NCT04369664 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
Study NCT04369664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
Study NCT03365635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
Description: Same as described in arm description
Study NCT04369664 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PCSK9 inhibitor
Description: Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
Study NCT04369664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered intravenously in accordance with product labeling and local standards.
Study NCT04369664 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ezetimibe 10mg
Description: Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
Study NCT04369664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered orally in accordance with product labeling and local standards.
Study NCT01998971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
Study NCT03424005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
Study NCT03424005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle.
Study NCT03809650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Description: macitentan 10 mg, film-coated tablet, oral use
Study NCT02475005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain self management app on smartphone
Study NCT03540615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1830839
Description: Dose escalation in healthy male subjects
Study NCT03540615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01912183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication through PHR outside clinic
Study NCT01912183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring device in PHR
Study NCT01912183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity and sleep monitor
Study NCT01246349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (Treatment Group)
Description: Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
Study NCT01246349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training (Control Group)
Description: Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
Study NCT03424005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle.
Study NCT01912183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and sleep monitor
Study NCT01912183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHR
Description: Access to their PHR
Study NCT01912183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHR
Description: Access to their PHR
Study NCT02510222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral magnesium sulfate
Description: Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
Study NCT02510222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02552810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steam clean
Description: Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).